CryoLife Announces Management Promotions(s management. Prior tojoining CryoLife i...)

"We are pleased to announce these well-deserved promotions within our management team," said Steven G. Anderson, CryoLife president and chief executive officer. "Bruce, Rich and Tim have each made substantial contributions to the success of the organization over the past several years, and we believe they will continue to enhance our ability to bring cutting-edge solutions to cardiac and vascular surgeons world-wide."

About CryoLife, Inc.

Founded in 1984, CryoLife, Inc. is a leader in the processing and distribution of implantable living human tissues for use in cardiac and vascular surgeries throughout the United States and Canada. The Company recently received FDA clearance for the CryoValve(R) SG pulmonary human heart valve, processed using CryoLife's proprietary SynerGraft(R) Technology. The Company's BioGlue(R) Surgical Adhesive is FDA approved as an adjunct to sutures and staples for use in adult patients in open surgical repair of large vessels. BioGlue is also CE marked in the European Community and approved in Canada and Australia for use in soft tissue repair. CryoLife distributes Hemostase MPH(R), a hemostatic agent, in much of the U.S. for use in cardiac and vascular surgery and in the United Kingdom and Germany for cardiac, vascular, and general surgery, subject to certain exclusions. The Company also distributes the CryoLife-O'Brien(R) stentless porcine heart valve, which is CE marked for distribution within the European Community.

For additional information about the company, visit CryoLife's Web site: http://www.cryolife.com

Media Contacts:

D. Ashley Lee Katie Brazel

Executive Vice President, Chief Fleishman Hillard

Financial Officer and Phone: 404-739-0150

Chief Operating Officer

Phone
'/>"/>